表紙
市場調査レポート

タンパク質医薬品の世界市場と製造技術

Global Markets and Manufacturing Technologies for Protein Drugs

発行 BCC Research 商品コード 63235
出版日 ページ情報 英文 176 pages
即納可能
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
タンパク質医薬品の世界市場と製造技術 Global Markets and Manufacturing Technologies for Protein Drugs
出版日: 2016年05月16日 ページ情報: 英文 176 pages
概要

世界のタンパク質医薬品市場規模は、2020年まで7.3%のCAGR (年間複合成長率) で推移し、2015年の1,747億米ドルから2020年までに2,487億米ドルに達すると予測されています。

当レポートは、世界のタンパク質医薬品市場について調査し、世界市場の動向分析、各技術の強み・弱みに関する議論、現在の市場規模と今後5年間の売上予測、デリバリー手法・副作用といった課題の評価、付属製品・特許保護に関する問題の検討、および主要企業のプロファイルなどをまとめ、お届けいたします。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 概要

  • 歴史
  • 治療用タンパク質の薬理学上の分類
  • 治療用タンパク質の分子レベルの分類
  • 製造技術

第4章 規制の諸側面

  • モノクローナル抗体
  • 治療用酵素
  • サイトカイン
  • ペプチドホルモン
  • ワクチン
  • 血液製剤
  • ペプチド抗体
  • リコール
  • 安全性に関する警告

第5章 新たな動き

  • モノクローナル抗体
  • ワクチン
  • サイトカイン
  • ペプチドホルモン
  • ペプチド抗体
  • 治療用酵素
  • 血液製剤
  • M&A

第6章 市場分析:タイプ別

  • 市場:タイプ別
  • ペプチドホルモン
  • ワクチン
  • 治療用酵素
  • モノクロナール抗体
  • サイトカイン
  • 血液因子
  • ペプチド抗体
  • 市場:地域別

第7章 市場分析:製造工程別

  • 市場:製造工程別
  • ペプチドホルモン
  • ワクチン
  • 治療用酵素
  • モノクロナール抗体
  • サイトカイン
  • 血液因子
  • ペプチド抗体

第8章 産業構造

  • ペプチドホルモン
  • ワクチン
  • 治療用酵素
  • モノクロナール抗体
  • サイトカイン
  • 血液因子
  • ペプチド抗体

第9章 特許分析

  • 特許:年度別
  • 特許:タイプ別
  • 特許:企業別
  • 特許:国別
  • 特許:出願者別

第10章 市場の現状

  • タンパク質治療市場に影響を及ぼしている要因

第11章 企業プロファイル

  • ABBVIE INC.
  • ACTAVIS INC.
  • ALEXION PHARMACEUTICALS
  • ALLERGAN PLC
  • AMGEN INC
  • APOTEX INC.
  • BAXALTA INC
  • BAYER PHARMA AG
  • BIOGEN INC.
  • BIOMARIN PHARMACEUTICAL INC
  • BIOTEST PHARMACEUTICALS CORP.
  • BRISTOL-MYERS SQUIBB
  • CSL LIMITED
  • ELI LILLY
  • F. HOFFMANN-LA ROCHE AG
  • FRESENIUS KABI USA
  • GLAXOSMITHKLINE
  • GRIFOLS USA LLC
  • HOSPIRA INC
  • JOHNSON & JOHNSON
  • MEDIMMUNE LLC
  • MERCK & CO, INC
  • MERCK KGAA
  • MYLAN INC.
  • NOVARTIS AG
  • NOVO NORDISK AG
  • OCTAPHARMA AG
  • PFIZER INC
  • PROTEIN SCIENCES CORP.
  • REVO BIOLOGICS INC.
  • SANDOZ
  • SANOFI INC
  • SEATTLE GENETICS INC.
  • SPECTRUM PHARMACEUTICALS INC
  • TAKEDA PHARMACEUTICAL U.S.A., INC
  • UCB COMPANY
  • SHIRE PLC (VIROPHARM INC.)
  • VERTEX PHARMACEUTICALS

第12章 付録−略語

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: BIO021E

REPORT HIGHLIGHTS

The global protein drugs market reached nearly $174.7 billion in 2015 and should reach nearly $248.7 billion by 2020 at a compound annual growth rate (CAGR) of 7.3% through 2020.

This report will provide:

  • An overview of the markets for each major class of protein in the segments therapeutic monoclonal antibodies, cytokines, peptide hormones, vaccines, and blood products
  • Analyses of global market trends, with data from 2014, estimates for 2015, and projections of compound annual growth rates (CAGRs) through 2020
  • Discussion covering the strength and weaknesses of each type of technology in light of the new technologies, growing competition, and changing customer needs
  • Examinations of current successes, including the size and sales forecast for each class in the next five years
  • Evaluation of challenges such as delivery methods and side effects
  • Consideration of issues regarding add-on products and patent protection
  • Company profiles of major players

SCOPE OF THE STUDY

The scope of this study covers manufacturing of protein drugs technologies. BCC Research analyzed each market and its applications, regulatory environment, technology, market projections and market shares. Technological issues include the latest trends and developments. This report covers the currently used six techniques in manufacturing of protein therapeutics, which includes fractionation from natural human/animal sources, microbial fermentation, cell culture, chemical synthesis, transgenics and embryonated eggs. The emerging market for enzyme inhibitors includes countries such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia and New Zealand. The protein drugs that are covered in this report are monoclonal antibodies, cytokines, peptide antibiotics, vaccines, enzymes and blood factors. The market is also analyzed on the basis of the manufacturing process used in making therapeutic protein drugs.

Also included in the report are relevant patent analysis and comprehensive profiles of companies that lead the manufacturing of the protein drug industry. Some of the major players of the market include Eli Lilly & Co., Abbvie Inc., F. Hoffmann-La Roche Ltd., Sanofi S.A., Novo Nordisk AG, Novartis AG, Merck & Co., Merck KGaA and Amgen Inc..

ANALYSTS' CREDENTIALS

The study has been carried out by a team of professionals in the biotechnology industry. The project manager is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has over 14 years of industry experience. She was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • CONTRIBUTIONS OF THE STUDY AND FOR WHOM
  • SCOPE OF THE STUDY
  • METHODOLOGY
  • INFORMATION SOURCES
  • ANALYSTS' CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - EXECUTIVE SUMMARY

  • SUMMARY TABLE: GLOBAL REVENUE FOR PROTEIN DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL REVENUE FOR PROTEIN DRUGS BY REGION, 2013-2020 ($ MILLIONS)

CHAPTER 3 - OVERVIEW

  • HISTORY
    • TABLE 1: EVOLUTION OF THERAPEUTIC PROTEINS
  • PHARMACOLOGICAL CLASSIFICATION OF THERAPEUTIC PROTEINS
    • PROTEIN THERAPEUTICS WITH ENZYMATIC OR REGULATORY ACTIVITY
      • By Replacing the Deficient or Abnormal Protein
      • By Augmenting an Existing Pathway
      • By Providing a Novel Function or Activity
    • PROTEIN THERAPEUTICS WITH SPECIAL TARGETING ACTIVITY
      • Interfering with a Molecule or Organism
      • Delivering Other Compounds or Proteins
    • PROTEIN VACCINES
  • MOLECULAR CLASSIFICATION OF THERAPEUTIC PROTEINS
    • CYTOKINES
      • Interferons
      • Interleukins
      • Colony Stimulating Factors
    • MONOCLONAL ANTIBODIES
    • BLOOD PRODUCTS
      • Alpha 1 Proteinase Inhibitor
      • Anti-Hemophilic Factor
      • Anti-Thrombin
      • C1-Esterase Inhibitor
      • Coagulation Factors
      • Immuno Globulins
      • Protein C
      • Thrombin
    • PEPTIDE ANTIBIOTICS
    • VACCINES
      • Live, Attenuated Vaccines
      • Inactivated/Killed Vaccines
      • Toxoid
      • Subunit/Conjugate
    • ENZYMES
      • Digestive Enzymes
      • Metabolic Enzymes/Lysosomal Enzymes
      • Other Enzymes
    • PEPTIDE HORMONES
      • Follicle Stimulating Hormone and Luteinizing Hormone
      • Growth Hormones
      • Erythropoietin
      • Insulin
  • MANUFACTURING TECHNOLOGIES
    • FRACTIONATION/ EXTRACTION FROM NATURAL SOURCES (HUMAN/ANIMAL)
      • TABLE 2: PROTEIN DRUGS MADE BY FRACTIONATION
    • MICROBIAL FERMENTATION AND BIOREACTORS
      • Bioreactors
        • TABLE 3: THERAPETIC DRUGS PRODUCED BY MICROBIAL FERMENTATION
    • TRANSGENICS
      • TABLE 4: PROTEIN DRUGS PRODUCED BY TRANSGENIC ANIMALS, PLANTS AND MICROORGANISMS
    • MAMMALIAN CELL CULTURE
      • TABLE 5: PROTEIN DRUGS MADE BY CELL CULTURE

CHAPTER 4 - REGULATORY ASPECTS

  • MONOCLONAL ANTIBODIES
    • TABLE 6: NEW APPROVALS OF MONOCLONAL ANTIBODIES, 2013-OCTOBER 2015
  • THERAPEUTIC ENZYMES
    • TABLE 7: NEW APPROVALS IN THERAPEUTIC ENZYMES, 2013-OCTOBER 2015
  • CYTOKINES
    • TABLE 8: NEW APPROVALS OF CYTOKINES, 2013-OCTOBER 2015
  • PEPTIDE HORMONES
    • TABLE 9: NEW APPROVALS OF PEPTIDE HORMONES, 2013-OCTOBER 2015
  • VACCINES
    • TABLE 10: NEW APPROVALS OF VACCINES, 2013-OCTOBER 2015
  • BLOOD PRODUCTS
    • TABLE 11: NEW APPROVALS OF BLOOD PRODUCTS, 2013-OCTOBER 2015
  • PEPTIDE ANTIBIOTICS
    • TABLE 12: NEW APPROVALS OF PEPTIDE ANTIBIOTICS, 2013-OCTOBER 2015
  • RECALLS
    • TABLE 13: RECALLS, 2013-OCTOBER 2015
  • SAFETY ALERTS
    • TABLE 14: SAFETY ALERTS, 2013-OCTOBER 2015

CHAPTER 5 - NEW DEVELOPMENTS

  • MONOCLONAL ANTIBODIES
    • TABLE 15: PIPELINE PRODUCTS OF MONOCLONAL ANTIBODIES
  • VACCINES
    • TABLE 16: PIPELINE PRODUCTS OF VACCINES
  • CYTOKINES
    • TABLE 17: PIPELINE PRODUCTS OF CYTOKINES
  • PEPTIDE HORMONES
    • TABLE 18 PIPELINE PRODUCTS IN PEPTIDE HORMONES
  • PEPTIDE ANTIBIOTICS
    • TABLE 19: PIEPLINES IN PEPTIDE ANTIBIOTICS
  • THERAPEUTIC ENZYMES
    • TABLE 20: PIPELINE PRODUCTS IN THERAPEUTIC ENZYMES
  • BLOOD PRODUCTS
    • TABLE 21: PIPELINE PRODUCTS IN BLOOD PRODUCTS
  • MERGERS AND ACQUISITIONS
    • TABLE 22 MERGERS AND ACQUISITIONS OF TOP PHARMACEUTICAL COMPANIES

CHAPTER 6 - MARKET ANALYSIS BY TYPE

  • MARKET BY TYPE
    • MARKET OVERVIEW
    • MARKET REVENUE
      • TABLE 23: GLOBAL REVENUE FOR PROTEIN DRUGS BY TYPE, THROUGH 2020 ($ MILLIONS)
      • FIGURE 1: GLOBAL REVENUE FOR PROTEIN DRUGS BY TYPE, 2013-2020 ($ MILLIONS)
    • MARKET SHARE
      • TABLE 24: MARKET SHARE OF PROTEIN DRUGS BY TYPE, 2014 (%)
      • FIGURE 2: MARKET SHARE OF PROTEIN DRUGS BY TYPE, 2014 (%)
  • PEPTIDE HORMONES
    • Market Overview
    • Market Revenue
      • TABLE 25: GLOBAL REVENUE FOR PEPTIDE HORMONES BY TYPE, THROUGH 2020 ($ MILLIONS)
      • FIGURE 3: GLOBAL REVENUE FOR PEPTIDE HORMONES BY TYPE, 2013-2020 ($ MILLIONS)
  • VACCINES
    • Market Overview
    • Market Revenue
      • TABLE 26: GLOBAL REVENUE FOR VACCINES BY TYPE, THROUGH 2020 ($ MILLIONS)
      • FIGURE 4: GLOBAL REVENUE FOR VACCINES BY TYPE, 2013-2020 ($ MILLIONS)
  • THERAPEUTIC ENZYMES
    • Market Overview
    • Market Revenue
      • TABLE 27: GLOBAL REVENUE FOR THERAPEUTIC ENZYMES BY TYPE, THROUGH 2020 ($ MILLIONS)
      • FIGURE 5: GLOBAL REVENUE FOR THERAPEUTIC ENZYMES BY TYPE, 2013-2020 ($ MILLIONS)
  • MONOCLONAL ANTIBODIES
    • Market Overview
    • Market Revenue
      • TABLE 28: GLOBAL REVENUE FOR MONOCLONAL ANTIBODIES BY TYPE, THROUGH 2020 ($ MILLIONS)
      • FIGURE 6: GLOBAL REVENUE FOR MONOCLONAL ANTIBODIES BY TYPE, 2013-2020 ($ MILLIONS)
  • CYTOKINES
    • Market Overview
    • Market Revenue
      • TABLE 29: GLOBAL REVENUE FOR CYTOKINES BY TYPE, THROUGH 2020 ($ MILLIONS)
      • FIGURE 7: GLOBAL REVENUE FOR CYTOKINES BY TYPE, 2013-2020 ($ MILLIONS)
  • BLOOD FACTORS
    • Market Overview
    • Market Revenue
      • TABLE 30: GLOBAL REVENUE FOR BLOOD FACTORS BY TYPE, THROUGH 2020 ($ MILLIONS)
      • FIGURE 8: GLOBAL REVENUE FOR BLOOD FACTORS BY TYPE, 2013-2020 ($ MILLIONS)
  • PEPTIDE ANTIBIOTICS
    • Market Overview
    • Market Revenue
      • TABLE 31: GLOBAL REVENUE FOR PEPTIDE ANTIBIOTICS BY TYPE, THROUGH 2020 ($ MILLIONS)
      • FIGURE 9: GLOBAL REVENUE FOR PEPTIDE ANTIBIOTICS BY TYPE, 2013-2020 ($ MILLIONS)
  • MARKET BY REGION
    • MARKET OVERVIEW
    • MARKET REVENUE
      • TABLE 32: GLOBAL REVENUE FOR PROTEIN DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
      • FIGURE 10: GLOBAL REVENUE FOR PROTEIN DRUGS BY REGION, 2013-2020 ($ MILLIONS)
    • MARKET SHARE
      • TABLE 33: MARKET SHARE OF PROTEIN DRUGS BY REGION, 2014 (%)
      • FIGURE 11: MARKET SHARE OF PROTEIN DRUGS BY REGION, 2014 (%)
  • PEPTIDE HORMONES
    • Market Overview
    • Market Revenue
      • TABLE 34: GLOBAL MARKET FOR PEPTIDE HORMONES BY REGION, THROUGH 2020 ($ MILLIONS)
      • FIGURE 12: GLOBAL MARKET FOR PEPTIDE HORMONES BY REGION, 2013-2020 ($ MILLIONS)
  • VACCINES
    • Market Overview
    • Market Revenue
      • TABLE 35: GLOBAL REVENUE FOR VACCINES BY REGION, THROUGH 2020 ($ MILLIONS)
      • FIGURE 13: GLOBAL REVENUE FOR VACCINES BY REGION, 2013-2020 ($ MILLIONS)
  • THERAPEUTIC ENZYMES
    • Market Overview
    • Market Revenue
      • TABLE 36: GLOBAL MARKET FOR THERAPEUTIC ENZYMES BY REGION, THROUGH 2020 ($ MILLIONS)
      • FIGURE 14: GLOBAL MARKET FOR THERAPEUTIC ENZYMES BY REGION, 2013-2020 ($ MILLIONS)
  • MONOCLONAL ANTIBODIES
    • Market Overview
    • Market Revenue
      • TABLE 37: GLOBAL REVENUE FOR MONOCLONAL ANTIBODIES BY REGION, THROUGH 2020 ($ MILLIONS)
      • FIGURE 15: GLOBAL REVENUE FOR MONOCLONAL ANTIBODIES BY REGION, 2013-2020 ($ MILLIONS)
  • CYTOKINES
    • Market Overview
    • Market Revenue
      • TABLE 38: GLOBAL REVENUE FOR CYTOKINES BY REGION, THROUGH 2020 ($ MILLIONS)
      • FIGURE 16: GLOBAL REVENUE FOR CYTOKINES BY REGION, 2013-2020 ($ MILLIONS)
  • BLOOD FACTORS
    • Market Overview
    • Market Revenue
      • TABLE 39: GLOBAL REVENUE FOR BLOOD FACTORS BY REGION, THROUGH 2020 ($ MILLIONS)
      • FIGURE 17: GLOBAL REVENUE FOR BLOOD FACTORS BY REGION, 2013-2020 ($ MILLIONS)
  • PEPTIDE ANTIBIOTICS
    • Market Overview
    • Market Revenue
      • TABLE 40: GLOBAL REVENUE FOR PEPTIDE ANTIBIOTICS BY REGION, THROUGH 2020 ($ MILLIONS)
      • FIGURE 18: GLOBAL REVENUE FOR PEPTIDE ANTIBIOTICS BY REGION, 2013-2020 ($ MILLIONS)

CHAPTER 7 - MARKET ANALYSIS BY MANUFACTURING PROCESS

  • MARKET BY MANUFACTURING PROCESS
    • MARKET OVERVIEW
    • MARKET REVENUE
      • TABLE 41: GLOBAL REVENUE FOR PROTEIN DRUGS BY MANUFACTURING PROCESS, THROUGH 2020 ($ MILLIONS)
      • FIGURE 19: GLOBAL REVENUE FOR PROTEIN DRUGS BY MANUFACTURING PROCESS, 2013-2020 ($ MILLIONS)
    • MARKET SHARE
      • TABLE 42: MARKET SHARE OF PROTEIN DRUGS BY MANUFACTURING PROCESS, 2014 (%)
      • FIGURE 20: MARKET SHARE OF PROTEIN DRUGS BY MANUFACTURING PROCESS, 2014 (%)
  • PEPTIDE HORMONES
    • Market Overview
    • Market Revenue
      • TABLE 43: GLOBAL REVENUE FOR PEPTIDE HORMONES BY MANUFACTURING PROCESS, THROUGH 2020 ($ MILLIONS)
      • FIGURE 21: GLOBAL REVENUE FOR PEPTIDE HORMONES BY MANUFACTURING PROCESS, 2013-2020 ($ MILLIONS)
  • VACCINES
    • Market Overview
    • Market Revenue
      • TABLE 44: GLOBAL REVENUE FOR VACCINES BY MANUFACTURING PROCESS, THROUGH 2020 ($ MILLIONS)
      • FIGURE 22: GLOBAL REVENUE FOR VACCINES BY MANUFACTURING PROCESS, 2013-2020 ($ MILLIONS)
  • THERAPEUTIC ENZYMES
    • Market Overview
    • Market Revenue
      • TABLE 45: GLOBAL REVENUE FOR THERAPEUTIC ENZYMES BY MANUFACTURING PROCESS, THROUGH 2020 ($ MILLIONS)
      • FIGURE 23: GLOBAL REVENUE FOR THERAPEUTIC ENZYMES BY MANUFACTURING PROCESS, 2013-2020 ($ MILLIONS)
  • MONOCLONAL ANTIBODIES
    • Market Overview
    • Market Revenue
      • TABLE 46: GLOBAL REVENUE FOR MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, THROUGH 2020 ($ MILLIONS)
      • FIGURE 24: GLOBAL REVENUE FOR MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, 2013-2020 ($ MILLIONS)
  • CYTOKINES
    • Market Overview
    • Market Revenue
      • TABLE 47: GLOBAL REVENUE FOR CYTOKINES BY MANUFACTURING PROCESS, THROUGH 2020 ($ MILLIONS)
      • FIGURE 25: GLOBAL REVENUE FOR CYTOKINES BY MANUFACTURING PROCESS, 2013-2020 ($ MILLIONS)
  • BLOOD FACTORS
    • Market Overview
    • Market Revenue
      • TABLE 48: GLOBAL REVENUE FOR BLOOD FACTORS BY MANUFACTURING PROCESS, THROUGH 2020 ($ MILLIONS)
      • FIGURE 26: GLOBAL REVENUE FOR BLOOD FACTORS BY MANUFACTURING PROCESS, 2013-2020 ($ MILLIONS)
  • PEPTIDE ANTIBIOTICS
    • Market Overview
    • Market Revenue
      • TABLE 49: GLOBAL REVENUE FOR PEPTIDE ANTIBIOTICS BY MANUFACTURING PROCESS, THROUGH 2020 ($ MILLIONS)
      • FIGURE 27: GLOBAL REVENUE FOR PEPTIDE ANTIBIOTICS BY MANUFACTURING PROCESS, 2013-2020 ($ MILLIONS)

CHAPTER 8 - INDUSTRY STRUCTURE

  • PEPTIDE HORMONES
    • MARKET LEADERS
      • TABLE 50: LEADING MANUFACTURERS/SUPPLIERS OF PEPTIDE HORMONES, 2014
    • MARKET SHARE
      • TABLE 51: MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR PEPTIDE HORMONES, 2014 (%)
      • FIGURE 28: MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR PEPTIDE HORMONES, 2014 (%)
  • VACCINES
    • MARKET LEADERS
      • TABLE 52: LEADING MANUFACTURERS/SUPPLIERS OF VACCINES, 2014
    • MARKET SHARE
      • TABLE 53: MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR VACCINES, 2014 (%)
      • FIGURE 29: MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR VACCINES, 2014 (%)
  • THERAPEUTIC ENZYMES
    • MARKET LEADERS
      • TABLE 54: LEADING MANUFACTURERS/SUPPLIERS OF THERAPEUTIC ENZYMES, 2014
    • MARKET SHARE
      • TABLE 55: MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR THERAPEUTIC ENZYMES, 2014 (%)
      • FIGURE 30: MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR THERAPEUTIC ENZYMES, 2014 (%)
  • MONOCLONAL ANTIBODIES
    • MARKET LEADERS
      • TABLE 56: LEADING MANUFACTURERS/SUPPLIERS OF MONOCLONAL ANTIBODIES, 2014
    • MARKET SHARE
      • TABLE 57: MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR MONOCLONAL ANTIBODIES, 2014 (%)
      • FIGURE 31: MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR MONOCLONAL ANTIBODIES, 2014 (%)
  • CYTOKINES
    • MARKET LEADERS
      • TABLE 58: LEADING MANUFACTURERS/SUPPLIERS OF CYTOKINES, 2014
    • MARKET SHARE
      • TABLE 59: MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR CYTOKINES, 2014 (%)
      • FIGURE 32: MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR CYTOKINES, 2014 (%)
  • BLOOD FACTORS
    • MARKET LEADERS
      • TABLE 60 LEADING MANUFACTURERS/SUPPLIERS OF THERAPEUTIC BLOOD PRODUCTS, 2014
    • MARKET SHARE
      • TABLE 61: MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR RECOMBINANT BLOOD PRODUCTS, 2014 (%)
      • FIGURE 33: MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR RECOMBINANT BLOOD PRODUCTS, 2014 (%)
  • PEPTIDE ANTIBIOTICS
    • MARKET LEADERS
      • TABLE 62: LEADING MANUFACTURERS/SUPPLIERS OF PEPTIDE ANTIBIOTICS, 2014
    • MARKET SHARE
      • TABLE 63: MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR PEPTIDE ANTIBIOTICS, 2014 (%)
      • FIGURE 34: MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR PEPTIDE ANTIBIOTICS, 2014 (%)

CHAPTER 9 - PATENT ANALYSIS

  • PATENTS BY YEAR
    • TABLE 64: NUMBER OF PATENTS BY YEAR, 2013-OCTOBER 2015
    • FIGURE 35: NUMBER OF PATENTS BY YEAR, 2013-OCTOBER 2015
  • PATENTS BY TYPE
    • TABLE 65: NUMBER OF PATENTS BY TYPE, 2013-OCTOBER 2015
    • FIGURE 36: NUMBER OF PATENTS BY TYPE, 2013-OCTOBER 2015
  • PATENTS BY COMPANY
    • TABLE 66: NUMBER OF PATENTS BY COMPANY, 2013-OCTOBER 2015
  • PATENTS BY COUNTRY
    • TABLE 67: NUMBER OF PATENTS BY COUNTRY, 2013-OCTOBER 2015
    • TABLE 68: PATENT SHARES BY COUNTRY, 2013-OCTOBER 2015 (%)
    • FIGURE 37: PATENT SHARES BY COUNTRY, 2013-OCTOBER 2015 (%)
  • PATENTS BY ASSIGNEE
    • TABLE 69: NUMBER OF PATENTS BY ASSIGNEE, 2013-OCTOBER 2015
    • FIGURE 38: NUMBER OF PATENTS BY ASSIGNEE, 2013-OCTOBER 2015

CHAPTER 10 - CURRENT SITUATION

  • FACTORS AFFECTING THE PROTEIN THERAPEUTIC MARKET
    • DRIVERS OF THE PROTEIN THERAPEUTIC MARKET
      • Prevalence of Chronic Diseases
      • Growing Aging Population
      • Advancements in Manufacturing Technologies
      • New Product Launches
      • Licensing Agreements
    • RESTRAINTS AND CHALLENGES OF THE MARKET
      • Price Controls
      • Regulatory Pressures
      • Entry of Biosimilars
      • Mergers and Acquisitions

CHAPTER 11 - COMPANY PROFILES

  • ABBVIE INC.
  • ACTAVIS INC.
  • ALEXION PHARMACEUTICALS
  • ALLERGAN PLC
  • AMGEN INC
  • APOTEX INC.
  • BAXALTA INC
  • BAYER PHARMA AG
  • BIOGEN INC.
  • BIOMARIN PHARMACEUTICAL INC
  • BIOTEST PHARMACEUTICALS CORP.
  • BRISTOL-MYERS SQUIBB
  • CSL LIMITED
  • ELI LILLY
  • F. HOFFMANN-LA ROCHE AG
  • FRESENIUS KABI USA
  • GLAXOSMITHKLINE
  • GRIFOLS USA LLC
  • HOSPIRA INC
  • JOHNSON & JOHNSON
  • MEDIMMUNE LLC
  • MERCK & CO, INC
  • MERCK KGAA
  • MYLAN INC.
  • NOVARTIS AG
  • NOVO NORDISK AG
  • OCTAPHARMA AG
  • PFIZER INC
  • PROTEIN SCIENCES CORP.
  • REVO BIOLOGICS INC.
  • SANDOZ
  • SANOFI INC
  • SEATTLE GENETICS INC.
  • SPECTRUM PHARMACEUTICALS INC
  • TAKEDA PHARMACEUTICAL U.S.A., INC
  • UCB COMPANY
  • SHIRE PLC (VIROPHARM INC.)
  • VERTEX PHARMACEUTICALS

CHAPTER 12 - APPENDIX I - ABBREVIATIONS

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL REVENUE FOR PROTEIN DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 1: EVOLUTION OF THERAPEUTIC PROTEINS
    • TABLE 2: PROTEIN DRUGS MADE BY FRACTIONATION
    • TABLE 3: THERAPETIC DRUGS PRODUCED BY MICROBIAL FERMENTATION
    • TABLE 4: PROTEIN DRUGS PRODUCED BY TRANSGENIC ANIMALS, PLANTS AND MICROORGANISMS
    • TABLE 5: PROTEIN DRUGS MADE BY CELL CULTURE
    • TABLE 6: NEW APPROVALS OF MONOCLONAL ANTIBODIES, 2013-OCTOBER 2015
    • TABLE 7: NEW APPROVALS IN THERAPEUTIC ENZYMES, 2013-OCTOBER 2015
    • TABLE 8: NEW APPROVALS OF CYTOKINES, 2013-OCTOBER 2015
    • TABLE 9: NEW APPROVALS OF PEPTIDE HORMONES, 2013-OCTOBER 2015
    • TABLE 10: NEW APPROVALS OF VACCINES, 2013-OCTOBER 2015
    • TABLE 11: NEW APPROVALS OF BLOOD PRODUCTS, 2013-OCTOBER 2015
    • TABLE 12: NEW APPROVALS OF PEPTIDE ANTIBIOTICS, 2013-OCTOBER 2015
    • TABLE 13: RECALLS, 2013-OCTOBER 2015
    • TABLE 14: SAFETY ALERTS, 2013-OCTOBER 2015
    • TABLE 15: PIPELINE PRODUCTS OF MONOCLONAL ANTIBODIES
    • TABLE 16: PIPELINE PRODUCTS OF VACCINES
    • TABLE 17: PIPELINE PRODUCTS OF CYTOKINES
    • TABLE 18: PIPELINE PRODUCTS IN PEPTIDE HORMONES
    • TABLE 19: PIEPLINES IN PEPTIDE ANTIBIOTICS
    • TABLE 20: PIPELINE PRODUCTS IN THERAPEUTIC ENZYMES
    • TABLE 21: PIPELINE PRODUCTS IN BLOOD PRODUCTS
    • TABLE 22: MERGERS AND ACQUISITIONS OF TOP PHARMACEUTICAL COMPANIES
    • TABLE 23: GLOBAL REVENUE FOR PROTEIN DRUGS BY TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 24: MARKET SHARE OF PROTEIN DRUGS BY TYPE, 2014 (%)
    • TABLE 25: GLOBAL REVENUE FOR PEPTIDE HORMONES BY TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 26: GLOBAL REVENUE FOR VACCINES BY TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 27: GLOBAL REVENUE FOR THERAPEUTIC ENZYMES BY TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 28: GLOBAL REVENUE FOR MONOCLONAL ANTIBODIES BY TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 29: GLOBAL REVENUE FOR CYTOKINES BY TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 30: GLOBAL REVENUE FOR BLOOD FACTORS BY TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 31: GLOBAL REVENUE FOR PEPTIDE ANTIBIOTICS BY TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 32: GLOBAL REVENUE FOR PROTEIN DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 33: MARKET SHARE OF PROTEIN DRUGS BY REGION, 2014 (%)
    • TABLE 34: GLOBAL MARKET FOR PEPTIDE HORMONES BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 35: GLOBAL REVENUE FOR VACCINES BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 36: GLOBAL MARKET FOR THERAPEUTIC ENZYMES BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 37: GLOBAL REVENUE FOR MONOCLONAL ANTIBODIES BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 38: GLOBAL REVENUE FOR CYTOKINES BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 39: GLOBAL REVENUE FOR BLOOD FACTORS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 40: GLOBAL REVENUE FOR PEPTIDE ANTIBIOTICS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 41: GLOBAL REVENUE FOR PROTEIN DRUGS BY MANUFACTURING PROCESS, THROUGH 2020 ($ MILLIONS)
    • TABLE 42: MARKET SHARE OF PROTEIN DRUGS BY MANUFACTURING PROCESS, 2014 (%)
    • TABLE 43: GLOBAL REVENUE FOR PEPTIDE HORMONES BY MANUFACTURING PROCESS, THROUGH 2020 ($ MILLIONS)
    • TABLE 44: GLOBAL REVENUE FOR VACCINES BY MANUFACTURING PROCESS, THROUGH 2020 ($ MILLIONS)
    • TABLE 45: GLOBAL REVENUE FOR THERAPEUTIC ENZYMES BY MANUFACTURING PROCESS, THROUGH 2020 ($ MILLIONS)
    • TABLE 46: GLOBAL REVENUE FOR MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, THROUGH 2020 ($ MILLIONS)
    • TABLE 47: GLOBAL REVENUE FOR CYTOKINES BY MANUFACTURING PROCESS, THROUGH 2020 ($ MILLIONS)
    • TABLE 48: GLOBAL REVENUE FOR BLOOD FACTORS BY MANUFACTURING PROCESS, THROUGH 2020 ($ MILLIONS)
    • TABLE 49: GLOBAL REVENUE FOR PEPTIDE ANTIBIOTICS BY MANUFACTURING PROCESS, THROUGH 2020 ($ MILLIONS)
    • TABLE 50: LEADING MANUFACTURERS/SUPPLIERS OF PEPTIDE HORMONES, 2014
    • TABLE 51: MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR PEPTIDE HORMONES, 2014 (%)
    • TABLE 52: LEADING MANUFACTURERS/SUPPLIERS OF VACCINES, 2014
    • TABLE 53: MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR VACCINES, 2014 (%)
    • TABLE 54: LEADING MANUFACTURERS/SUPPLIERS OF THERAPEUTIC ENZYMES, 2014
    • TABLE 55: MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR THERAPEUTIC ENZYMES, 2014 (%)
    • TABLE 56: LEADING MANUFACTURERS/SUPPLIERS OF MONOCLONAL ANTIBODIES, 2014
    • TABLE 57: MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR MONOCLONAL ANTIBODIES, 2014 (%)
    • TABLE 58: LEADING MANUFACTURERS/SUPPLIERS OF CYTOKINES, 2014
    • TABLE 59: MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR CYTOKINES, 2014 (%)
    • TABLE 60: LEADING MANUFACTURERS/SUPPLIERS OF THERAPEUTIC BLOOD PRODUCTS, 2014
    • TABLE 61: MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR RECOMBINANT BLOOD PRODUCTS, 2014 (%)
    • TABLE 62: LEADING MANUFACTURERS/SUPPLIERS OF PEPTIDE ANTIBIOTICS, 2014
    • TABLE 63: MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR PEPTIDE ANTIBIOTICS, 2014 (%)
    • TABLE 64: NUMBER OF PATENTS BY YEAR, 2013-OCTOBER 2015
    • TABLE 65: NUMBER OF PATENTS BY TYPE, 2013-OCTOBER 2015
    • TABLE 66: NUMBER OF PATENTS BY COMPANY, 2013-OCTOBER 2015
    • TABLE 67: NUMBER OF PATENTS BY COUNTRY, 2013-OCTOBER 2015
    • TABLE 68: PATENT SHARES BY COUNTRY, 2013-OCTOBER 2015 (%)
    • TABLE 69: NUMBER OF PATENTS BY ASSIGNEE, 2013-OCTOBER 2015

LIST OF FIGURES

  • SUMMARY FIGURE: GLOBAL REVENUE FOR PROTEIN DRUGS BY REGION, 2013-2020 ($ MILLIONS)
    • FIGURE 1: GLOBAL REVENUE FOR PROTEIN DRUGS BY TYPE, 2013-2020 ($ MILLIONS)
    • FIGURE 2: MARKET SHARE OF PROTEIN DRUGS BY TYPE, 2014 (%)
    • FIGURE 3: GLOBAL REVENUE FOR PEPTIDE HORMONES BY TYPE, 2013-2020 ($ MILLIONS)
    • FIGURE 4: GLOBAL REVENUE FOR VACCINES BY TYPE, 2013-2020 ($ MILLIONS)
    • FIGURE 5: GLOBAL REVENUE FOR THERAPEUTIC ENZYMES BY TYPE, 2013-2020 ($ MILLIONS)
    • FIGURE 6: GLOBAL REVENUE FOR MONOCLONAL ANTIBODIES BY TYPE, 2013-2020 ($ MILLIONS)
    • FIGURE 7: GLOBAL REVENUE FOR CYTOKINES BY TYPE, 2013-2020 ($ MILLIONS)
    • FIGURE 8: GLOBAL REVENUE FOR BLOOD FACTORS BY TYPE, 2013-2020 ($ MILLIONS)
    • FIGURE 9: GLOBAL REVENUE FOR PEPTIDE ANTIBIOTICS BY TYPE, 2013-2020 ($ MILLIONS)
    • FIGURE 10: GLOBAL REVENUE FOR PROTEIN DRUGS BY REGION, 2013-2020 ($ MILLIONS)
    • FIGURE 11: MARKET SHARE OF PROTEIN DRUGS BY REGION, 2014 (%)
    • FIGURE 12: GLOBAL MARKET FOR PEPTIDE HORMONES BY REGION, 2013-2020 ($ MILLIONS)
    • FIGURE 13: GLOBAL REVENUE FOR VACCINES BY REGION, 2013-2020 ($ MILLIONS)
    • FIGURE 14: GLOBAL MARKET FOR THERAPEUTIC ENZYMES BY REGION, 2013-2020 ($ MILLIONS)
    • FIGURE 15: GLOBAL REVENUE FOR MONOCLONAL ANTIBODIES BY REGION, 2013-2020 ($ MILLIONS)
    • FIGURE 16: GLOBAL REVENUE FOR CYTOKINES BY REGION, 2013-2020 ($ MILLIONS)
    • FIGURE 17: GLOBAL REVENUE FOR BLOOD FACTORS BY REGION, 2013-2020 ($ MILLIONS)
    • FIGURE 18: GLOBAL REVENUE FOR PEPTIDE ANTIBIOTICS BY REGION, 2013-2020 ($ MILLIONS)
    • FIGURE 19: GLOBAL REVENUE FOR PROTEIN DRUGS BY MANUFACTURING PROCESS, 2013-2020 ($ MILLIONS)
    • FIGURE 20: MARKET SHARE OF PROTEIN DRUGS BY MANUFACTURING PROCESS, 2014 (%)
    • FIGURE 21: GLOBAL REVENUE FOR PEPTIDE HORMONES BY MANUFACTURING PROCESS, 2013-2020 ($ MILLIONS)
    • FIGURE 22: GLOBAL REVENUE FOR VACCINES BY MANUFACTURING PROCESS, 2013-2020 ($ MILLIONS)
    • FIGURE 23: GLOBAL REVENUE FOR THERAPEUTIC ENZYMES BY MANUFACTURING PROCESS, 2013-2020 ($ MILLIONS)
    • FIGURE 24: GLOBAL REVENUE FOR MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, 2013-2020 ($ MILLIONS)
    • FIGURE 25: GLOBAL REVENUE FOR CYTOKINES BY MANUFACTURING PROCESS, 2013-2020 ($ MILLIONS)
    • FIGURE 26: GLOBAL REVENUE FOR BLOOD FACTORS BY MANUFACTURING PROCESS, 2013-2020 ($ MILLIONS)
    • FIGURE 27: GLOBAL REVENUE FOR PEPTIDE ANTIBIOTICS BY MANUFACTURING PROCESS, 2013-2020 ($ MILLIONS)
    • FIGURE 28: MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR PEPTIDE HORMONES, 2014 (%)
    • FIGURE 29: MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR VACCINES, 2014 (%)
    • FIGURE 30: MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR THERAPEUTIC ENZYMES, 2014 (%)
    • FIGURE 31: MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR MONOCLONAL ANTIBODIES, 2014 (%)
    • FIGURE 32: MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR CYTOKINES, 2014 (%)
    • FIGURE 33: MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR RECOMBINANT BLOOD PRODUCTS, 2014 (%)
    • FIGURE 34: MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR PEPTIDE ANTIBIOTICS, 2014 (%)
    • FIGURE 35: NUMBER OF PATENTS BY YEAR, 2013-OCTOBER 2015
    • FIGURE 36: NUMBER OF PATENTS BY TYPE, 2013-OCTOBER 2015
    • FIGURE 37: PATENT SHARES BY COUNTRY, 2013-OCTOBER 2015 (%)
    • FIGURE 38: NUMBER OF PATENTS BY ASSIGNEE, 2013-OCTOBER 2015
Back to Top